Clinicians are offering early access to Grail’s multi-cancer early detection (MCED) test while awaiting a full NHS trial readout and a concurrent FDA regulatory decision after the program missed a key endpoint. The interim use raises questions about how to interpret trial limitations and whether the evidence base supports broader implementation. The debate centers on the gap between real-world clinical pathways and trial endpoints, with physicians weighing practical demand against the need for definitive regulatory-grade data. With the endpoint miss now shaping decision-making, the next FDA determination and complete dataset are likely to influence near-term adoption strategies for MCED testing networks.